A carregar...
Phase I study of anti‐CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B‐cell non‐Hodgkin lymphoma
Inotuzumab ozogamicin (CMC‐544), a humanized anti‐CD22 antibody conjugated to the potent cytotoxic antibiotic calicheamicin, targets the CD22 antigen expressed on the majority of B‐cell non‐Hodgkin lymphomas. This phase I study assessed the tolerability, safety, pharmacokinetics, and preliminary eff...
Na minha lista:
| Publicado no: | Cancer Sci |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2012
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7659250/ https://ncbi.nlm.nih.gov/pubmed/22335424 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1349-7006.2012.02241.x |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|